Renata Ferrarotto
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
14
all conditions, ClinicalTrials.gov
NIH grants tied to them
2
NIH RePORTER
Trial papers
29
PubMed author-name match
Trials
Studies that name Renata Ferrarotto as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07162480 · Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)M.D. Anderson Cancer Center · recruiting · Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT06046482 · Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaM.D. Anderson Cancer Center · terminated · Head Neck, Squamous Cell Carcinoma of Head and Neck · principal investigator
- Ph2NCT05884320 · Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersM.D. Anderson Cancer Center · active not recruiting · Gland, Salivary Gland Cancers · principal investigator
- Ph2NCT05535023 · Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell CarcinomaM.D. Anderson Cancer Center · withdrawn · Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer · principal investigator
- Ph2NCT05027633 · Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)M.D. Anderson Cancer Center · recruiting · Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses · principal investigator
- Ph1NCT04973683 · AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic CancerM.D. Anderson Cancer Center · completed · Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma · principal investigator
- Ph1/Ph2NCT04220775 · Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell CancerM.D. Anderson Cancer Center · terminated · Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck · principal investigator
- Ph2NCT04030455 · Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerM.D. Anderson Cancer Center · active not recruiting · Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8 · principal investigator
- Ph2NCT03990571 · Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaM.D. Anderson Cancer Center · completed · Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT03799445 · Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaM.D. Anderson Cancer Center · terminated · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · principal investigator
- Ph1NCT03144778 · Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell CancerM.D. Anderson Cancer Center · completed · Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 · principal investigator
- Ph2NCT02882282 · Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial NeoplasiaM.D. Anderson Cancer Center · completed · Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia · principal investigator
- N/ANCT02662608 · Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)M.D. Anderson Cancer Center · completed · Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT01154920 · Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaM.D. Anderson Cancer Center · active not recruiting · Head and Neck Squamous Cell Carcinoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic CarcinomaR01CA292385 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $370,575 awarded in 2026Same name and institution; not confirmed by an ID
- Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic CarcinomaR03DE031333 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2023 · $162,000 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:22 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- 423 citationsRCR 15.1
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.N Engl J Med · 2022290 citationsRCR 20.0
- Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.Clin Cancer Res · 2021135 citationsRCR 7.2
- Phase 2 study of pembrolizumab in patients with advanced rare cancers.J Immunother Cancer · 2020123 citationsRCR 5.7
- A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.Ann Oncol · 2018117 citationsRCR 3.8
- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.Clin Cancer Res · 2020117 citationsRCR 4.1
- Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.J Am Acad Dermatol · 201799 citationsRCR 3.8
- ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.J Immunother Cancer · 202291 citationsRCR 6.3
- High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial.Radiother Oncol · 202185 citationsRCR 3.8
- 84 citationsRCR 4.2